Abstract
Aim: The current experiment was to develop and validate a straight forward RP-HPLC methodology for the determination of Cilnidipine.
 Methodology: UV spectroscopy was used to estimate Cilnidipine. Action separation of Cilnidipine was achieved by employing a C18 column. Mobile phase combination of methanol: water (90:10 v/v) was tense at the flow of 1 ml/min. Detection was performed at 241 nm. Validation parameters were evaluated in line with the International conference on harmonization (ICH) Q2R1 guidelines.
 Results: The standardization curve was linear within the varying concentration of 2-10 mg/ml for Cilnidipine with parametric statistic (r2) equal to 0.999. The tactic was found to be accurate (101.66% recovery), precise (intraday, 1.65 and inter day, 1.38) and robust (% RSD was calculated to be 0.66, 0.58 and 0.81 for variation in mobile phase composition, wave length and flow velocity respectively) for the analysis of Cilnidipine.
 Conclusion: The developed method has passed all the validation tests and can be successfully applied to estimate the presence of Cilnidipine in bulk as well as in pharmaceutical formulations.
Highlights
In the current scenario, hypertension or high blood pressure is one of the most fatal cardiovascular diseases
High blood pressure can affect anyone at any age, but it is more common in persons who have a family history of the condition, who are overweight or obese and have diabetes
The prevalence of hypertensive cases may be minimalized by use of several antihypertensive drugs e.g. calcium channel blockers, β-blockers, α-blockers, angiotensin converting enzyme inhibitors, diuretics, and angiotensin II type 1 receptor blockers [1]
Summary
Hypertension or high blood pressure is one of the most fatal cardiovascular diseases It is called silent killer because its symptoms are unrevealed till any major damage occurs in the body. It is a multifaceted disease associated with kidney As a result, it is one of the most under-diagnosed and under-treated medical disorders over the world. Cilnidipine (CL) has been extensively studied and demonstrated as calcium channel blocker in preclinical and clinical development phases. It blocks the N-type and Ltype calcium channels and dilates both arterioles and venules resulting in lowering the pressure in the capillary bed [2]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
